DATE

Jonathan Milner Issues Statement Responding to the Glass Lewis Report

Retrieved on: 
Lunedì, Ottobre 23, 2023
ACT, MAKE, ITS, TAX, FOR, PAST, FAIR, DATE, AS, UPDATE, SET, ANY, NO, AMERICA, FCA, EUROPEAN UNION, BY, FUTURE, FINANCIAL, III, TIME, UPON, NOT, EACH, AND, ALL, PER, THIS, OF, EXPRESS, AWARE, IS, NORTH, USE, IT, Glass fiber, Medical device, Audit, EU

T: +44 7733 265 198 / E: [email protected]

Key Points: 
  • T: +44 7733 265 198 / E: [email protected]
    T: +44 (0)20 3709 5700 / E: [email protected]
    T: +1 646 677 1811 / E: [email protected]
    THIS DOCUMENT HAS BEEN ISSUED BY DR. JONATHAN MILNER ("DR. MILNER").
  • DR. MILNER STRONGLY ADVISES ALL SHAREHOLDERS OF THE COMPANY TO READ THE PROXY STATEMENT AND OTHER PROXY MATERIALS AS THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION.
  • THE VIEWS EXPRESSED HEREIN REPRESENT THE OPINIONS OF DR. MILNER AS OF THE DATE HEREOF.
  • DR. MILNER HAS NOT SOUGHT OR OBTAINED CONSENT FROM ANY THIRD PARTY TO USE ANY STATEMENTS OR INFORMATION CONTAINED HEREIN.

Jonathan Milner Issues Statement Responding to ISS Report

Retrieved on: 
Lunedì, Ottobre 16, 2023
MAKE, ACT, III, AWARE, NO, AMERICA, NOT, PAST, TIME, DATE, THIS, AS, NORTH, USE, ANY, OF, IT, FOR, UPON, FINANCIAL, FCA, ITS, SET, IS, TAX, EXPRESS, EUROPEAN UNION, ALL, FAIR, UPDATE, BY, FUTURE, EACH, AND, Glass fiber, Medical device, Audit, EU

T: +44 7733 265 198 / E: [email protected]

Key Points: 
  • T: +44 7733 265 198 / E: [email protected]
    T: +44 (0)20 3709 5700 / E: [email protected]
    T: +1 646 677 1811 / E: [email protected]
    THIS DOCUMENT HAS BEEN ISSUED BY DR. JONATHAN MILNER ("DR. MILNER").
  • DR. MILNER STRONGLY ADVISES ALL SHAREHOLDERS OF THE COMPANY TO READ THE PROXY STATEMENT AND OTHER PROXY MATERIALS AS THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION.
  • THE VIEWS EXPRESSED HEREIN REPRESENT THE OPINIONS OF DR. MILNER AS OF THE DATE HEREOF.
  • DR. MILNER HAS NOT SOUGHT OR OBTAINED CONSENT FROM ANY THIRD PARTY TO USE ANY STATEMENTS OR INFORMATION CONTAINED HEREIN.

Jonathan Milner releases presentation to Abcam plc shareholders, outlining reasons to reject Danaher's bid and strategic vision for the Company

Retrieved on: 
Lunedì, Ottobre 16, 2023
ACT, MAKE, III, AWARE, NO, AMERICA, NOT, PAST, TIME, DATE, THIS, AS, NORTH, USE, ANY, OF, IT, FOR, UPON, PER, FINANCIAL, FCA, ITS, SET, IS, TAX, EXPRESS, EUROPEAN UNION, ALL, FAIR, UPDATE, BY, FUTURE, EACH, AND, Glass fiber, Medical device, Audit, EU

DR. MILNER STRONGLY ADVISES ALL SHAREHOLDERS OF THE COMPANY TO READ THE PROXY STATEMENT AND OTHER PROXY MATERIALS AS THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION.

Key Points: 
  • DR. MILNER STRONGLY ADVISES ALL SHAREHOLDERS OF THE COMPANY TO READ THE PROXY STATEMENT AND OTHER PROXY MATERIALS AS THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION.
  • THE VIEWS EXPRESSED HEREIN REPRESENT THE OPINIONS OF DR. MILNER AS OF THE DATE HEREOF.
  • DR. MILNER IS NOT RESPONSIBLE TO ANY PERSON FOR PROVIDING ADVICE IN RELATION TO THE SUBJECT MATTER OF THIS DOCUMENT.
  • DR. MILNER HAS NOT SOUGHT OR OBTAINED CONSENT FROM ANY THIRD PARTY TO USE ANY STATEMENTS OR INFORMATION CONTAINED HEREIN.

Anson and Cable Car Send Letter to MEI Pharma Stockholders

Retrieved on: 
Martedì, Ottobre 10, 2023
Partnership, Acquisition, Common, Letter, DATE, CARD, Biotechnology, Failure, SIGN, Clinical trial, Hoarding, SAN, MEI, Hand, Security (finance), Research, TIME, Holding company, Pharmaceutical industry, Property management, Cryptocurrency, Tobacco, Mail, Infinity, By-law

TORONTO and SAN FRANCISCO, Oct. 10, 2023 (GLOBE NEWSWIRE) -- Anson Funds (“Anson”) and Cable Car Capital LLC (“Cable Car” and, together with Anson, “we” or “us”), which collectively beneficially own approximately 19.9% of the outstanding common stock of MEI Pharma, Inc. (the “Company” or “MEIP”) (Nasdaq: MEIP), today announced that they have delivered a letter to MEIP stockholders and filed new definitive consent materials with the Securities and Exchange Commission in connection with their solicitation of written consents from stockholders in lieu of a stockholder meeting to remove the entire Board of Directors of MEIP for cause.  

Key Points: 
  • The full text of the letter to MEIP stockholders follows:
    IT IS TIME FOR CHANGE AT MEI PHARMA, INC.
    Anson Funds (“Anson”) and Cable Car Capital LLC (“Cable Car” and, together with Anson, “we” or “us”) collectively beneficially own approximately 19.9% of the outstanding common stock of MEI Pharma, Inc. (the “Company” or “MEIP”), making us the Company’s largest stockholders.
  • We wish we could say the same about the current Board, which has remained steadfast in refusing to return capital to stockholders.
  • Based on the stockholders’ rejection of the merger, it is clear that fellow stockholders shared our beliefs.
  • We believe MEIP stockholders deserve a Board that will truly look out for stockholders’ best interest and ensure management accountability.

Jonathan Milner issues Open Letter to shareholders of Abcam plc

Retrieved on: 
Martedì, Ottobre 10, 2023
MAKE, ACT, III, AWARE, NO, AMERICA, NOT, PAST, TIME, DATE, THIS, AS, NORTH, USE, ANY, OF, IT, FOR, UPON, FINANCIAL, FCA, ITS, SET, IS, TAX, EXPRESS, EUROPEAN UNION, ALL, FAIR, UPDATE, BY, FUTURE, EACH, AND, Glass fiber, Medical device, Audit, EU

T: +44 7733 265 198 / E: [email protected]

Key Points: 
  • T: +44 7733 265 198 / E: [email protected]
    T: +44 (0)20 3709 5700 / E: [email protected]
    T: +1 646 677 1811 / E: [email protected]
    THIS DOCUMENT HAS BEEN ISSUED BY DR. JONATHAN MILNER ("DR. MILNER").
  • DR. MILNER STRONGLY ADVISES ALL SHAREHOLDERS OF THE COMPANY TO READ THE PROXY STATEMENT AND OTHER PROXY MATERIALS AS THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION.
  • THE VIEWS EXPRESSED HEREIN REPRESENT THE OPINIONS OF DR. MILNER AS OF THE DATE HEREOF.
  • DR. MILNER HAS NOT SOUGHT OR OBTAINED CONSENT FROM ANY THIRD PARTY TO USE ANY STATEMENTS OR INFORMATION CONTAINED HEREIN.

DATE Fintech Show: Scripting a new chapter in Saudi Arabia's Fintech Revolution

Retrieved on: 
Lunedì, Ottobre 16, 2023
Survival, JW Marriott Hotels, Growth, DATE, Arms industry, Fintech

DATE Fintech Show, co-located with DATE AI Show, will be held on December 11th and 12th, 2023 in Riyadh bringing together leading financial experts, policymakers, investors, and innovators to come together and chart the course of Saudi Arabia's Fintech revolution.

Key Points: 
  • DATE Fintech Show, co-located with DATE AI Show, will be held on December 11th and 12th, 2023 in Riyadh bringing together leading financial experts, policymakers, investors, and innovators to come together and chart the course of Saudi Arabia's Fintech revolution.
  • DATE Fintech Show, co-located with DATE AI Show, is scheduled to take place at the JW Marriott Hotel in Riyadh on December 11th and 12th, 2023.
  • Presently, there are more than 147 fintech startups operating within Saudi Arabia, aligning with its goal of hosting 525 active fintech companies by 2030.
  • At the DATE Fintech Show in Riyadh, we delve into the transformative impact of Fintech solutions, reshaping Saudi Arabia's financial future."

Anson And Cable Car Send Letter to MEI Pharma Stockholders

Retrieved on: 
Martedì, Settembre 26, 2023
SIGN, CARD, Partnership, Failure, DATE, Biotechnology, Clinical trial, Research, Hoarding, Acquisition, SAN, Security (finance), MEI, Letter, TIME, Hand, Common, Holding company, Pharmaceutical industry, Property management, Tobacco, Mail, By-law, Infinity

TORONTO and SAN FRANCISCO, Sept. 26, 2023 (GLOBE NEWSWIRE) -- Anson Funds (“Anson”) and Cable Car Capital LLC (“Cable Car” and, together with Anson, “we” or “us”), which collectively beneficially own approximately 19.9% of the outstanding common stock of MEI Pharma, Inc. (the “Company” or “MEIP”) (Nasdaq: MEIP), today announced that they have delivered a letter to MEIP stockholders and filed definitive consent materials with the Securities and Exchange Commission in connection with their solicitation of written consents from stockholders in lieu of a stockholder meeting to remove the entire Board of Directors of MEIP for cause.

Key Points: 
  • The full text of the letter to MEIP stockholders follows:
    IT IS TIME FOR CHANGE AT MEI PHARMA, INC.
    Anson Funds (“Anson”) and Cable Car Capital LLC (“Cable Car” and, together with Anson, “we” or “us”) collectively beneficially own approximately 19.9% of the outstanding common stock of MEI Pharma, Inc. (the “Company” or “MEIP”), making us the Company’s largest stockholders.
  • We wish we could say the same about the current Board, which has remained steadfast in refusing to return capital to stockholders.
  • Based on the stockholders’ rejection of the merger, it is clear that fellow stockholders shared our beliefs.
  • We believe MEIP stockholders deserve a Board that will truly look out for stockholders’ best interest and ensure management accountability.

Newly inaugurated Yashobhoomi (IICC Dwarka) to host Trescon's DATE 2023 with Finance Minister Smt. Nirmala Sitharaman amongst the dignitaries

Retrieved on: 
Giovedì, Settembre 21, 2023
Data Security Council of India, DATE, Excitation, Small Innovative Missions for Planetary Exploration, The Honourable, Fintech, Electronics, KEK digital accelerator, Esports, Government, Parliament, Federation, DSCI, Operational technology, Virtual reality, Ecosystem, Robotics, IICC - Dwarka Sector 25 metro station, STPI, Software Technology Parks of India, Video game, Cryptocurrency, Transformers: Cyberverse

NEW DELHI, Sept 21, 2023 - (ACN Newswire) - Excitement surrounds Trescon's Digital Acceleration & Transformation Expo (DATE) as the Honorable Finance Minister Smt.

Key Points: 
  • NEW DELHI, Sept 21, 2023 - (ACN Newswire) - Excitement surrounds Trescon's Digital Acceleration & Transformation Expo (DATE) as the Honorable Finance Minister Smt.
  • Nirmala Sitharaman confirms to speak at the event and highlight India's financial innovation and FinTech revolution.
  • With our Finance Minister joining the line-up of dignitaries and speakers, the event is well poised to bring the FinTech community together and augment our overall digital ecosystem."
  • Boasting over 100 global speakers and 3,000 participants, DATE 2023 promises enlightening insights into the latest tech trends, opportunities, challenges, and practical success stories.

Dr. Jonathan Milner opposes Danaher's acquisition of Abcam and calls for EGM to replace Board

Retrieved on: 
Giovedì, Settembre 14, 2023
MAKE, ACT, AS, UPON, FOR, TAX, OF, NO, PAST, ITS, TIME, EACH, DATE, FINANCIAL, FUTURE, AND, IT, III, NORTH, BY, NOT, UPDATE, ALL, THIS, AMERICA, SET, USE, FCA, EUROPEAN UNION, AWARE, EXPRESS, IS, ANY, FAIR, Medical device, Audit, EU

T: +44 (0)20 3709 5700 / E: [email protected]

Key Points: 
  • T: +44 (0)20 3709 5700 / E: [email protected]
    T: +1 646 677 1811 / E: [email protected]
    THIS DOCUMENT HAS BEEN ISSUED BY DR. JONATHAN MILNER ("DR. MILNER").
  • THE VIEWS EXPRESSED HEREIN REPRESENT THE OPINIONS OF DR. MILNER AS OF THE DATE HEREOF.
  • DR. MILNER IS NOT RESPONSIBLE TO ANY PERSON FOR PROVIDING ADVICE IN RELATION TO THE SUBJECT MATTER OF THIS DOCUMENT.
  • DR. MILNER HAS NOT SOUGHT OR OBTAINED CONSENT FROM ANY THIRD PARTY TO USE ANY STATEMENTS OR INFORMATION CONTAINED HEREIN.

SAVE THE DATE: Zealand Pharma to host Obesity R&D Event in London on December 5, 2023

Retrieved on: 
Venerdì, Settembre 8, 2023
Webcast, Obesity, Zealand Pharma, DATE, Prevalence, Fine chemical

SAVE THE DATE: Zealand Pharma to host Obesity R&D Event in London on December 5, 2023

Key Points: 
  • SAVE THE DATE: Zealand Pharma to host Obesity R&D Event in London on December 5, 2023
    Copenhagen, Denmark, September 8, 2023 – Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no.
  • 20045078), a biotechnology company focused on the discovery and development of innovative peptide-based medicines, today announced that it will host an Obesity R&D Event in London on December 5, 2023 with management and external scientific experts in obesity.
  • “The growing prevalence of people living with obesity and associated comorbidities represents one of the biggest challenges for healthcare systems globally.
  • At Zealand, our robust and differentiated pipeline of drug candidates may help shape the future management of obesity”, said Adam Steensberg, President and Chief Executive Officer at Zealand Pharma.